Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2001

View Archived Issues

HIF-1 gene therapy product in clinical trial at U. of Pittsburgh Medical Center

Neovastat pivotal trial for third cancer indication approved in U.S. and Canada

Enzon seeks FDA approval to clinically evaluate PEG-paclitaxel

Effects of CGP-3466 investigated in models of Parkinson's disease

DNA vaccine for malaria to be developed using PLASmin Complexes

BresaGen's lead anticancer compound E21R licensed to British Biotech

Viragen staged to begin U.S. clinical trials with Omniferon

Avanir begins late-stage clinical trials with new drug for neurological disorders

ETA receptor antagonists in various stages of clinical testing at Icos-Texas Biotechnology

Clinical trial commences for new antiangiogenic agent discovered by OSI and Pfizer

DU-127090 will be codeveloped by Lundbeck and Solvay for schizophrenia

Antiviral drugs acquired by Novartis from SB

Zeldox status in Europe updated by Pfizer

Elan/Incara partnership plans immediate entry into pivotal IBD trials for OP-2000

Global rights for novel Japanese antiviral agent granted to Lilly

Name change and recent TB4 research results announced by the former Alpha 1 Biomedicals

L-739758 preserves coronary flow reserve during progressive coronary arteriostenosis in pigs

BP-2-94: an H3 receptor agonist prodrug with an interesting antiinflammatory/antinociceptive profile

New potassium channel modulators synthesized and tested by NeuroSearch

Recent patent covers Lilly's new subtype-selective metabotropic glutamate receptor antagonists

Aventis team describes preparation and use of new cell adhesion, migration inhibitors

Chemokine receptor antagonists in GlaxoSmithKline portfolio

Novel antiinflammatory agents described by Bayer group

Inhibitors of PTP1B and their use covered in patent issued to Merck Frosst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...